Oruka Therapeutics Inc's stock surged 9.00% in pre-market trading on Monday, following a significant analyst upgrade that boosted investor confidence in the company's prospects.
The sharp increase came after Leerink Partners raised its price target for Oruka Therapeutics to $86 from $58, representing a nearly 50% increase in the firm's valuation expectation for the company.